Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
Article
Lieberman, Frank S, Wang, Meihua, Robins, H Ian et al. (2019). Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 103(4), 878-886. 10.1016/j.ijrobp.2018.11.008
Lieberman, Frank S, Wang, Meihua, Robins, H Ian et al. (2019). Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 103(4), 878-886. 10.1016/j.ijrobp.2018.11.008
Lieberman, Frank S; Wang, Meihua; Robins, H Ian; Tsien, Christina; Curran, Walter J; Werner-Wasik, Maria; Smith, Ryan P; Schultz, Christopher; Hartford, Alan C; Zhang, Peixin; Mehta, Minesh P